IGEA Pharma N.V.: IGEA to get SIX further approval to the 2021 annual report disclosure
IGEA Pharma N.V. / Key word(s): Annual Results/Annual Results
IGEA to get SIX further approval to the 2021 annual report disclosure
Hoofddorp, the Netherlands, 09 August 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
On request of the statutory auditors, even if the 2021 Annual Report is completed, an extra time to review and write the Independent auditor's report is needed.
In accordance with SIX’s approval, this press release sets out the relevant section of the decision:
“I. The exemption application of IGEA (Issuer) dated 25 July 2022 requesting an
hoc publicity (art. 53 LR in connection with the DAH) concerning this decision
until Tuesday, 09 August 2022, 07.30 am CET, at the latest. The notice must
- the unaltered reproduction of the wording of para. I. of this decision,
placed in a prominent position;
- the reasons for the application of the Issuer requesting a third
Extension of the deadline to publish its 2021 annual report and to file
such report with SIX Exchange Regulation AG”
IGEA Pharma N.V. focuses through its Joint Venture on industrial CO2 supercritical extraction of CBD and other valuable components from their vegetable matrices for health prevention, pharma, food&beverage and other selected industries, with an innovative early-stage commercial and highly diversifiable pipeline. The company aims to become a center of excellence on highly controlled vegetable matrices and their industrial extraction technology. On the other hand, Igea operates on preventative health-tech products and devices, commercializing an Alzheimer’s prevention set (which
includes ’Alz1’, an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded ‘Alz1 Tab’ designed to reduce blood heavy metals content) and expects to integrate
the non-bound copper detection-based pipeline with a diabetes type II prevention set in the next future. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARSCoV-2 related antibodies.
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl
This document constitutes neither an offer to buy nor to subscribe securities and either this document
nor any part of it should form the basis of any investment decision in IGEA. The information contained
in this press release has been carefully prepared. However, IGEA bears and assumes no liability of
whatever kind for the correctness and completeness of the information provided herein. IGEA does not
assume an obligation of whatever kind to update or correct information contained in this press release
whether as a result of new information, future events or for other reasons. This publication may contain
specific forward-looking statements and assessments or intentions concerning IGEA and its business.
Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors
which may result in a substantial divergence between the actual results, financial situation, development,
or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the
background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes
no responsibility to update forward looking statements or to adapt them to future events or developments,
except as maybe required by law.
End of Inside Information
|IGEA Pharma N.V.
|2123 WT Hoofddorp
|+31 23 568 9494
|Regulated Unofficial Market in Frankfurt; SIX Swiss Exchange
|EQS News ID:
|End of Announcement
|EQS News Service